개요

Development Stage

Product Candidate Target Indication Discovery Pre-clinical Phase1 Phase2 Phase3
RZ-001
Hepatocellular carcinoma Phase1

RZ-001

  • Stage : Phase I
  • Indication : Hepatocellular carcinoma
  • Target : Telomerase reverse transcriptase (TERT)
  • Delivery Vehicle : Adenovirus
  • Dose Route : Intra-tumoral injection
RZ-001_immune therapy combination
Hepatocellular carcinoma Phase1

RZ-001_immune therapy combination

  • Stage : Phase I
  • Indication : Hepatocellular carcinoma
  • Target : Telomerase reverse transcriptase (TERT)
  • Delivery Vehicle : Adenovirus
  • Dose Route : Intra-tumoral injection (Adenovirus) / Intravenous (Immune checkpoint inhibitor)
  • Partnership

RZ-001 (GBM)
Glioblastoma Phase1

RZ-001 (GBM)

  • Stage : Phase I
  • Indication : Glioblastoma
  • Target : Telomerase reverse transcriptase (TERT)
  • Delivery Vehicle : Adenovirus
  • Dose Route : Intra-tumoral injection
RZ-002
Glioblastoma Pre-clinical

RZ-002

  • Stage : Pre-clinical
  • Indication : Glioblastoma
  • Target : Telomerase reverse transcriptase (TERT)
  • Delivery Vehicle : Adenovirus
  • Dose Route : Intra-tumoral injection
RZ-003
Alzheimer Discovery

RZ-003

  • Stage : Discovery
  • Indication : Alzheimer
  • Target : Apolipoprotein E (APOE4)
  • Delivery Vehicle : Adeno-associated virus (AAV)
  • Dose Route : Intra-cisternal injection
RZ-004
Retinitis Pigmentosa Pre-clinical

RZ-004

  • Stage : Pre-clinical
  • Indication : Retinitis Pigmentosa
  • Target : Mutant Rhodopsin
  • Delivery Vehicle : Adeno-associated virus (AAV)
  • Dose Route : Sub-retinal injection
New platform
- Discovery

New platform

  • New platform
  • Stage : Discovery